Indian Pharmaceutical company develop Coronavirus medicine in ₹103 or $1.35
In a statement, officials said that it will be available in pan India in 7 to 10 days.
Indians Regulator Approved Medicine
India’s drug regulator approved the manufacturing and marketing of the oral drug called “Favipiravir” under the brand name “FabiFlu”. The company published a letter regarding this approval on its website.
According to this letter, this approval has been granted based on the evaluation of data and in consultation with the Subject Expert Committee, as part of the accelerated approval process, considering the emergency situation and unmet medical need of the COVID-19 outbreak.
Dr. Monika Tandon, VP, Head of Clinical Development, Glenmark said, “The need of the hour is to help Healthcare professionals by enabling patients to get treatment at home and help in faster recovery of patients, save lives”.
Cost of COVID-19 Drug
The drug will be available in the pack of 34 tablets costs ₹3,500, which could be ₹103 for each tablet. However, every patient must have signed informed consent before treatment initiation, according to the letter published by the company. But, they also said that the drug has wide therapeutic safety margins.
The drug will be strictly provided on prescription and used only after the patient’s consent. The drug will be available globally under the provision of emergency use authorization.